Recruitment is open for the Feline trial, a clinical study investigating a potential treatment for fibrosis (excess fibrous connective tissue) associated with obesity-induced fatty liver disease.
Losartan is a drug normally used to treat hypertension, but studies by Dr Jude Oben and colleagues, have shown that it is a significant anti-fibrotic agent in experimental models of fatty liver disease. The Feline study is the first time that losartan is being tested in patients for this condition.
“This research is timely because as obesity levels rise, the incidence of fatty liver disease is dramatically increasing,” says Dr Oben, a consultant hepatologist at the Trust, the project lead, and trustee and scientific advisor to the Obesity Action Campaign.
“This is the fourth clinical trial into obesity-related liver disease that our group has conducted using the Clinical Research Facility at St Thomas’. Having specialist equipment and expertise all located in the same place is very useful for the clinical research that we do.”
Find out more about our Clinical Research Facility.
To find out more about the trial please contact jude.oben@gstt.nhs.uk
Posted on Friday 11th May 2012